| Market Cap | 4.19B | P/E | - | EPS this Y | 10.00% | Ern Qtrly Grth | - |
| Income | -54.3M | Forward P/E | 17.46 | EPS next Y | 15.90% | 50D Avg Chg | -3.00% |
| Sales | 2.04B | PEG | 0.48 | EPS past 5Y | - | 200D Avg Chg | -6.00% |
| Dividend | N/A | Price/Book | 9.45 | EPS next 5Y | 42.10% | 52W High Chg | -23.00% |
| Recommedations | 2.80 | Quick Ratio | 1.06 | Shares Outstanding | 237.74M | 52W Low Chg | 10.00% |
| Insider Own | 0.38% | ROA | 3.28% | Shares Float | 118.52M | Beta | - |
| Inst Own | 99.53% | ROE | - | Shares Shorted/Prior | 6.80M/6.49M | Price | 17.63 |
| Gross Margin | 50.72% | Profit Margin | -2.66% | Avg. Volume | 1,020,375 | Target Price | 21.10 |
| Oper. Margin | 8.68% | Earnings Date | Aug 2 | Volume | 5,847,494 | Change | 0.46% |
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.
| Evercore ISI Group | Outperform | Feb 17, 22 |
| HC Wainwright & Co. | Neutral | Dec 27, 21 |
| Barclays | Equal-Weight | Dec 27, 21 |
| Evercore ISI Group | In-Line | Dec 23, 21 |
| HC Wainwright & Co. | Buy | Aug 5, 21 |
| Barclays | Overweight | Jul 13, 21 |
| Credit Suisse | Outperform | May 6, 21 |
| Morgan Stanley | Overweight | May 6, 21 |
| Barclays | Overweight | Mar 3, 21 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schlesinger Michael A. | EVP, GC and Secretar.. EVP, GC and Secretary | Aug 18 | Sell | 20.08 | 45,015 | 903,901 | 87,637 | 08/18/21 |
| Schlesinger Michael A. | EVP, GC and Secretar.. EVP, GC and Secretary | Aug 18 | Option | 6.28 | 45,015 | 282,694 | 128,652 | 08/18/21 |